<DOC>
	<DOCNO>NCT00220558</DOCNO>
	<brief_summary>The objective study compare Cypher Select-TM Sirolimus Eluting Stent ( SES ) SONIC-TM Bare Metal Stent ( BMS ) treatment Chronic Total Occlusion lesion ( CTO ) . The primary hypothesis , 8-month follow-up , minimal luminal diameter ( MLD ) coronary segment treat stent implantation CTO lesion significantly large use SES compare BMS . The treated segment define segment cover stent ( ) plus 5 mm proximally distally stent ( ) .</brief_summary>
	<brief_title>GISSOC II : Sirolimus Eluting Stent Versus Bare Metal Stent Chronic Total Coronary Occlusions</brief_title>
	<detailed_description>This multicenter , prospective , randomize study conduct 22 center Italy . All patient meet eligibility criterion randomize Cypher Select-TM Stent SONIC-TM Stent . Patients repeat angiography 8 month clinical follow-up 2 year . The study population consist 150 patient single chronic total occlusion native coronary artery reference diameter 2.75 mm 3.75 mm . The occlusion dilatable balloon angioplasty fully cover &lt; 2 stent ≤33 mm length . The CTO define obstruction native coronary artery , least 30 day old , luminal continuity Thrombolysis Myocardial Infarction ( TIMI ) flow grade 0 1 . Following confirmation eligibility criterion successful pre-dilating CTO , patient randomize 1:1 ratio receive SES CYPHER SELECT Stent BMS SONIC Stent . The coronary angiogram assess core laboratory Quantitative Coronary Angiography . Quantitative angiographic parameter include minimal luminal diameter , binary restenosis rate , total reocclusion rate , late luminal loss , evaluate 8 month . The incidence clinical event , include death , myocardial infarction , target vessel revascularization , stent thrombosis , evaluate 8 , 12 24 month .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Occlusion</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Stable unstable angina pectoris document silent ischemia ; Planned treatment single de novo chronic totally occlude ( CTO ) native coronary artery reference diameter 2.75 mm 3.75 mm ; The target lesion fully cover ≤ 2 stent ≤33 mm length ; The target CTO least 30 day old ; The target CTO successfully cross guide wire dilate balloon ; Myocardial infarction within 30 day territory target CTO ; Unprotected leave main coronary artery disease ; Target CTO graft ; Target CTO stented segment ; Presence lesion vessel , require angioplasty treatable stent ( ) use target CTO ; More one CTO require PCI ; Target CTO diseased side branch &gt; 2.0 mm diameter ; Target CTO pretreated nonballoon device atherectomy laser thrombectomy device ; Patient treat coronary brachytherapy ; The patient ejection fraction ≤ 30 % ; The patient impair renal function ( creatinine &gt; 3.0 mg/dl ) ; The patient know allergy aspirin , clopidogrel bisulfate ticlopidine , heparin , sirolimus , contrast medium stainless steel manage medically ; The patient need therapy warfarin ; The patient life expectancy le 24 month ; Recipient heart transplant ; The patient currently participate investigational drug another device study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Percutaneous Transluminal Coronary Angioplasty</keyword>
	<keyword>Bare metal stent</keyword>
	<keyword>drug elute stent</keyword>
</DOC>